This free script provided by
JavaScript Kit


Catalog #:

IN0094-1mg USD156.0

References for KN-62 :

1. Schuler, A. D., Si, J., Mueller, L., Simon, J. A., and Collins, S. J. KN-62 analogues as potent differentiating agents of HL-60 cells. Leuk Res, 31: 683-689, 2007.

2. Penolazzi, L., Bianchini, E., Lambertini, E., Baraldi, P. G., Romagnoli, R., Piva, R., and Gambari, R. N-Arylpiperazine modified analogues of the P2X7 receptor KN-62 antagonist are potent inducers of apoptosis of human primary osteoclasts. J Biomed Sci, 12: 1013-1020, 2005.

3. Hubner, K. and Phi-van, L. KN-62, a selective inhibitor of Ca(2+)/calmodulin-dependent protein kinase II, inhibits the lysozyme pre-mRNA splicing in myelomonocytic HD11 cells. Biochem Biophys Res Commun, 319: 405-409, 2004.

4. Muhl, H., Hofler, S., and Pfeilschifter, J. Inhibition of lipopolysaccharide/ATP-induced release of interleukin-18 by KN-62 and glyburide. Eur J Pharmacol, 482: 325-328, 2003.

5. Baraldi, P. G., del Carmen Nunez, M., Morelli, A., Falzoni, S., Di Virgilio, F., and Romagnoli, R. Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor. J Med Chem, 46: 1318-1329, 2003.

6. Haralambieva, I., Iankov, I., Mitev, V., and Mitov, I. KN-62 enhances Chlamydia pneumoniae-induced p44/p42 mitogen-activated protein kinase activation in murine fibroblasts and attenuates in vitro infection. FEMS Microbiol Lett, 215: 149-155, 2002.

Certificate of Analysis/MSDS is available upon request with lot number

Home | Contact | Support | Privacy Policy, Terms Warranty | Apycom jQuery Menus